Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study.
Eef L TheunissenNadia R P W HuttenNatasha L MasonStefan W ToennesKim Paula Colette KuypersEliza B de Sousa Fernandes PernaJohannes G RamaekersPublished in: British journal of pharmacology (2017)
JWH-018 dosing in the present study resulted in drug concentrations that were generally low and not fully representative of common use. Yet initial impairments of neurocognitive function and subjective feelings of high did emerge despite low levels of JWH-018 in serum. Higher doses are needed to obtain a more representative risk profile of JWH-018.